Ligand Pharmaceuticals Incorporated
NASDAQ:LGNDBiotechnology
+$2.89 today
- Market cap
- $5.98B
- Beta
- 1.04
- P/E (TTM)
- 34.4
- EPS (TTM)
- $7.72
Volume 0.38M
Average 0.22M
LGND Total Non-current Liabilities
All obligations due after more than one year.
Ligand Pharmaceuticals IncorporatedNASDAQ: LGND
Total Non-current Liabilities · Q2 FY2026 · quarter ended Jun 2026
Total non-current liabilities rises 2017.1% from a year ago
Total non-current liabilities stood at $1.17B at the end of Q2 FY2026, up 2017.1% from a year earlier and up 137.1% from the prior quarter. Over 3 fiscal years it compounded at +96.8% a year.
Context
- Total non-current liabilities amounted to 53.6% of total assets at the end of Q2 FY2026, up 47.8 pp from a year earlier.
- Total non-current liabilities increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total non-current liabilities keeps rising in the next quarterly balance sheet after a +2017.1% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Non-current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 505.98M USD
- Year-over-year change
- +581.7%
- 4-year CAGR
- +3.9%
| Period | Period end | Total Non-current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 505.98M | +581.7% |
| FY2024 | 2024-12-31 | 74.22M | +6.8% |
| FY2023 | 2023-12-31 | 69.52M | +4.7% |
| FY2022 | 2022-12-31 | 66.37M | -84.7% |
| FY2021 | 2021-12-31 | 434.77M | — |
Total Non-current Liabilities vs competitors
How LGND compares with its peers on the latest reported figures
- LGND's Jun 2026 total non-current liabilities of $1.17B is the 6th highest of the 10 companies compared; the peer median is $5.42B.
- Its year-over-year change of +2017.1% is the highest of 10, against a peer median of -2.6%.
- Total non-current liabilities amounts to 53.6% of total assets for LGND, versus a peer median of 43.3%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $99.36B | +1.9% | +0.7% | 73.5% | |
| Jun 2026 | $82.99B | +4.6% | +12.6% | 41.3% | |
| Jun 2026 | $58.45B | -2.6% | +7.2% | 61.1% | |
| Jun 2026 | $46.66B | -6.0% | +3.2% | 53.2% | |
| Jun 2026 | $5.42B | +916.7% | +76.6% | 43.3% | |
| Jun 2026 | $1.17B | +2017.1% | +96.8% | 53.6% | |
| Jun 2026 | $803.29M | +14.5% | -16.1% | 144.0% | |
| Jul 2026 | $288.55M | -6.4% | +2.4% | 11.6% | |
| Jun 2026 | $216.12M | -41.9% | -2.8% | 2.7% | |
| Mar 2026 | $15.22M | -83.2% | -34.8% | 3.0% | |
| Peer median (excluding LGND) | $5.42B | -2.6% | +2.4% | 43.3% | |
Competitors are the stored peer set for LGND. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 19.52M | 45.01M | 22.95M | 72.31M | 174.93M |
| Short-term Investments | 321.59M | 166.86M | 147.36M | 183.86M | 558.59M |
| Net Receivables | 91.65M | 35.04M | 39.31M | 42.45M | 61.05M |
| Inventory | 27.33M | 13.29M | 23.97M | 14.11M | 9.13M |
| Other Current Assets | 4.67M | 2.27M | 2.66M | 16.9M | 28.58M |
| Total Current Assets | 464.75M | 263.6M | 237.43M | 331.56M | 832.27M |
| Property, Plant & Equipment (Net) | 32.6M | 27.49M | 25.06M | 24.81M | 10.79M |
| Goodwill | 105.67M | 105.67M | 103.37M | 105.25M | 101.54M |
| Intangible Assets | 386.8M | 352.64M | 299.61M | 266.65M | 422.32M |
| Long-term Investments | 0 | 3M | 111.61M | 10.91M | 183.58M |
| Tax Assets | 35.73M | 8.53M | 214K | 72K | 8.35M |
| Other Non-current Assets | 272.03M | 1.74M | 9.92M | 202.53M | 1.79M |
| Total Non-current Assets | 832.84M | 499.07M | 549.79M | 610.22M | 728.37M |
| Total Assets | 1.3B | 762.67M | 787.22M | 941.77M | 1.56B |
| Account Payables | 8.4M | 5.31M | 2.43M | 5.23M | 3.24M |
| Short-term Debt | 0 | 76.7M | 0 | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 1.2M | 1.24M |
| Deferred Revenue | 654K | 976K | 1.84M | 1.9M | 621K |
| Other Current Liabilities | 22.57M | 6.26M | 4.94M | (3.2M) | 6.81M |
| Total Current Liabilities | 41.67M | 98.81M | 16.78M | 37.11M | 37.45M |
| Long-term Debt | 320.72M | 0 | 0 | 0 | 446.19M |
| Deferred Tax Liabilities | 30.86M | 30.62M | 31.62M | 32.52M | 52.61M |
| Deferred Revenue (Non-current) | 0 | 44K | 15.14M | 0 | 0 |
| Other Non-current Liabilities | 80.94M | 25.38M | 17M | 35.88M | 2.97M |
| Total Non-current Liabilities | 434.77M | 66.37M | 69.52M | 74.22M | 505.98M |
| Total Liabilities | 476.43M | 165.18M | 86.3M | 111.34M | 543.43M |
| Common Stock | 17K | 17K | 18K | 20K | 20K |
| Retained Earnings | 449.09M | 450.86M | 503.02M | 498.98M | 608.09M |
| Accumulated OCI | (917K) | (984K) | (817K) | (5.94M) | 8.46M |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 821.16M | 597.49M | 700.91M | 830.44M | 1.02B |
| Total Debt | 324.39M | 87.75M | 6.17M | 7.11M | 451.49M |
| Net Debt | 304.86M | 42.74M | (16.79M) | (65.2M) | 276.56M |
Ligand Pharmaceuticals Incorporated
NASDAQ:LGND
Intrinsic Alpha fair value
Locked
Current Price
$298.71
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.